Concord Biotech Ltd
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
- Market Cap ₹ 15,315 Cr.
- Current Price ₹ 1,464
- High / Low ₹ 2,452 / 1,345
- Stock P/E 42.8
- Book Value ₹ 173
- Dividend Yield 0.73 %
- ROCE 28.4 %
- ROE 21.4 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 18.7% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 28.2%
Cons
- Stock is trading at 8.41 times its book value
- Company has high debtors of 159 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 340 | 436 | 512 | 617 | 713 | 853 | 1,017 | 1,200 | 1,188 | |
| 195 | 256 | 308 | 289 | 439 | 509 | 585 | 693 | 702 | |
| Operating Profit | 145 | 180 | 205 | 328 | 274 | 344 | 432 | 507 | 486 |
| OPM % | 43% | 41% | 40% | 53% | 38% | 40% | 42% | 42% | 41% |
| 18 | 17 | 31 | 14 | 23 | 35 | 34 | 44 | 48 | |
| Interest | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 1 | 0 |
| Depreciation | 18 | 19 | 21 | 28 | 50 | 54 | 54 | 54 | 59 |
| Profit before tax | 144 | 178 | 213 | 313 | 241 | 320 | 409 | 496 | 475 |
| Tax % | 30% | 33% | 21% | 25% | 26% | 26% | 26% | 25% | |
| 100 | 118 | 169 | 235 | 179 | 238 | 305 | 373 | 357 | |
| EPS in Rs | 105.66 | 124.48 | 177.65 | 247.44 | 187.76 | 22.76 | 29.13 | 35.65 | 34.15 |
| Dividend Payout % | 0% | 21% | 22% | 0% | 3% | 30% | 30% | 25% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 19% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 27% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 21% |
| Last Year: | 21% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 585 | 673 | 761 | 990 | 1,098 | 1,282 | 1,515 | 1,802 |
| 22 | 9 | 52 | 89 | 62 | 32 | 10 | 3 | |
| 69 | 72 | 118 | 94 | 144 | 191 | 164 | 219 | |
| Total Liabilities | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 |
| 189 | 230 | 240 | 546 | 573 | 593 | 575 | 795 | |
| CWIP | 3 | 19 | 141 | 18 | 74 | 173 | 211 | 51 |
| Investments | 151 | 229 | 199 | 142 | 74 | 138 | 244 | 335 |
| 343 | 285 | 361 | 477 | 592 | 611 | 668 | 854 | |
| Total Assets | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 79 | 155 | 167 | 207 | 246 | 265 | 245 | ||
| -42 | -114 | -195 | -112 | -158 | -155 | -160 | ||
| -37 | -43 | 31 | -100 | -85 | -99 | -99 | ||
| Net Cash Flow | 0 | -1 | 3 | -4 | 3 | 12 | -14 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 236 | 133 | 131 | 105 | 119 | 117 | 125 | 159 |
| Inventory Days | 381 | 310 | 312 | 503 | 434 | 430 | 331 | 286 |
| Days Payable | 210 | 112 | 201 | 152 | 185 | 190 | 150 | 135 |
| Cash Conversion Cycle | 407 | 331 | 242 | 456 | 368 | 357 | 306 | 310 |
| Working Capital Days | 275 | 186 | 159 | 177 | 163 | 153 | 166 | 193 |
| ROCE % | 27% | 25% | 32% | 21% | 26% | 28% | 28% |
Documents
Announcements
-
Successful Completion Of NAFDAC Inspection
8 Oct - NAFDAC inspection at Valthera OSD Unit-2 completed Oct 6–7, 2025; compliance affirmed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Oct - Certificate under Reg 74(5) confirming dematerialisation actions for quarter ended Sep 30, 2025.
-
Closure of Trading Window
25 Sep - Trading window closed Oct 1, 2025 until 48 hours after unaudited results for quarter ended 30 Sep 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Sep - Of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015 on 19th September, 2025 at 11:00 AM IST
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Sep - Analyst/institutional investor meetings on 17 Sep 2025 with Jefferies India in New Delhi; discussions on public information.
Concalls
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptPPT
-
Sep 2023Transcript PPT
Business Profile[1]
Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.